Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01730872 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model

A Phase 4 study, sponsored by ORA.

Completed
Registry status
Phase 4
Development phase
16
Enrollment target

NCT01730872 is a Phase 4 study that has completed, run by ORA. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01730872, a Phase 4 study, has completed, sponsored by ORA.

COMPLETED
Registry status
Phase 4
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: Chronic Allergic Inflammation assessed using confocal microscopy Ocular itching Conjunctival redness

Interventions

  • DRUG Prednisolone Sodium Phosphate Ophthalmic Solution 1%
  • DRUG Tears Naturale II Ophthalmic Solution

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2012-11
Est. Completion 2012-12
Phase Phase 4

Sponsor

ORA

19 total trials

What the Registry Record Tells You About NCT01730872

The ClinicalTrials.gov registry entry for NCT01730872 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ORA, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Prednisolone Sodium Phosphate Ophthalmic Solution 1% is the first listed.

NCT01730872 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01730872 about?

NCT01730872 is a clinical study titled "Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model". The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: Chronic Aller...

What is the current status of trial NCT01730872?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2012-11. Estimated completion is 2012-12.

What interventions are being tested in trial NCT01730872?

The interventions under investigation include: Prednisolone Sodium Phosphate Ophthalmic Solution 1% (DRUG), Tears Naturale II Ophthalmic Solution (DRUG).

Who is sponsoring clinical trial NCT01730872?

This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.